Change in Liver Function in Durvalumab Plus Tremelimumab Treatment for Unresectable Hepatocellular Carcinoma.
Nobuharu TamakiNami MoriShintaro TakakiKeiji TsujiToshifumi TadaShinichiro NakamuraHironori OchiToshie MashibaMasao DoisakiHiroyuki MarusawaHaruhiko KobashiHideki FujiiChikara OgawaMichiko NonogiHirotaka AraiYasushi UchidaNaohito UrawaRyoichi NaritaTakehiro AkahaneMasahiko KondoYutaka YasuiKaoru TsuchiyaNamiki IzumiMasayuki KurosakiPublished in: Anticancer research (2024)
DT treatment can maintain liver function throughout the treatment period. Maintaining liver function is crucial in managing HCC, and this is an advantage of using DT treatment as a first-line treatment for unresectable HCC.